How Commercial Insurers, Self-Insured Employers, PBMs, and Manufacturers Are Turning GLP-1 Pharmacy Benefits Into Active Managed-Access Operating Systems and Where the Infrastructure Opportunity Sits

Key Takeaways

• 43% of large firms now cover GLP-1s for weight loss (2025)
• Utilization rose faster than expected, becoming top drug spend line
• Persistence low: ~50% stop GLP-1 within a year
• PBMs launch managed-access programs with cost caps and coaching
• Manufacturers open direct-to-employer channels, pricing at $449 per dose

Pulse Analysis

The rapid expansion of GLP‑1 agonists from obesity treatment to cardiovascular risk reduction, obstructive sleep apnea and non‑cirrhotic MASH has upended traditional pharmacy benefit models. Unlike legacy drugs, the eligible population now spans tens of millions of commercially insured adults, and monthly list prices hover between $1,000 and $1,200. Employers and carriers can no longer rely on simple tiered formularies; they must design eligibility thresholds, diagnostic criteria and utilization controls that balance clinical benefit with escalating spend.

Payers and PBMs are responding by building managed‑access ecosystems that embed cost caps, outcome guarantees and behavioral interventions. Evernorth’s EncircleRx, covering 9 million lives, offers a 15% cost cap or a 3:1 savings guarantee and has saved plans roughly $200 million since 2024. Optum’s Weight Engage pairs GLP‑1 access with specialist navigation, coaching and lifestyle programs, while UnitedHealthcare’s Total Weight Support requires enrollment in weight‑loss coaching platforms as a coverage gate. These infrastructures aim to improve adherence, reduce waste and provide data for outcomes‑based contracting.

Manufacturers are bypassing traditional PBM channels, launching direct‑to‑employer offerings such as Lilly’s Employer Connect at $449 per dose and Novo Nordisk’s partnership with Waltz Health. However, the persistence problem remains stark: meta‑regression shows about 50% of patients discontinue within a year, and only one in twelve stay on therapy after three years. This churn creates a lucrative market for platforms that can monitor adherence, manage tapering, and tie reimbursement to measurable health outcomes. As employers assume greater payer responsibilities, the convergence of data analytics, coaching services and outcomes‑based contracts will shape the next wave of cardiometabolic benefit design.